RECRUITING

Hormonal, Metabolic, and Signaling Interactions in PAH

Talk to us

Conditions

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionScleroderma Associated Pulmonary Arterial HypertensionAppetite Suppressant Associate PAHPulmonary arterial hypertension

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.

Official Title

Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension

Quick Facts

Study Start:2012-09
Study Completion:2032-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01884051

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
  2. 2. Age 0-90, age 12-90 for skin biopsy
  3. 1. Other diagnosis
  4. 2. Age greater than 90, age less than 12 or greater than 90 for skin biopsy
  5. 1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
  6. 2. 0-90
  7. 3. Subjects with reasonably easy access to clinic for blood collection and other testing
  8. 4. Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing
  9. 1. Other diagnosis
  10. 2. 0-90
  11. 3. Subjects with difficulty reaching clinic for blood collection and other testing
  12. 4. Subjects unable to tolerate fasting state
  13. 1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
  14. 2. 7-90
  15. 1. Other diagnosis
  16. 2. Age less than 7 or greater than 90
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Kelly L Fox
CONTACT
800-288-0378
Kelly.Burke@vumc.org
Shannon Cordell, BSN
CONTACT
615-343-8277
shannon.eason@vumc.org

Principal Investigator

James E Loyd, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

  • James E Loyd, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2012-09
Study Completion Date2032-07

Study Record Updates

Study Start Date2012-09
Study Completion Date2032-07

Terms related to this study

Keywords Provided by Researchers

  • Pulmonary arterial hypertension

Additional Relevant MeSH Terms

  • Idiopathic Pulmonary Arterial Hypertension
  • Heritable Pulmonary Arterial Hypertension
  • Scleroderma Associated Pulmonary Arterial Hypertension
  • Appetite Suppressant Associate PAH